REFERENCES
- Bouza C., Angeles M., Muñoz A., Maria A. J. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction. 2004; 99: 811–828, [PUBMED], [INFOTRIEVE], [CSA]
- Chick J., Howlett H., Morgan M. Y., Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): A 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol & Alcoholism. 2000; 35: 176–187, [CSA], [CROSSREF]
- Forest Laboratories, Inc. Campral® (acamprosate calcium) ddelayed-release tablets prescribing information. 2004
- Garbutt J. C., West S. L., Carey T. S., Lohr K. N., Crews F. T. Pharmacological treatment of alcohol dependence: A review of the evidence. Journal of the American Medical Association. 1999; 281: 1318–1325, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Namkoong K., Lee B. O., Lee P. G., Choi M. J., Lee E. Acamprosate in Korean alcohol-dependent patients: A multi-centre, randomized, double-blind, placebo-controlled study. Alcohol & Alcoholism. 2003; 38: 135–141, [CSA], [CROSSREF]
- Pelc I., Verbanck P., Le Bon O., Gavrilovic M., Lion K., Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. British Journal of Psychiatry. 1997; 170: 73–77, [CSA]